Nature inspires new highly specific drugs and organic products

The best place to seek novel compounds for pharmaceutical drugs, alternative energy sources, and a host of industrial applications, is within natural systems that have evolved over millions of years. Scientists now realise that the precise molecular arrangements within natural pathways in organisms have been highly tuned for specific processes and provide both compounds that can be exploited directly and vital information over how to synthesise new products by mimicking biochemical processes. The bright future for research and development around such natural products was discussed recently at a conference organised by the European Science Foundaton (ESF), and the European Cooperation in the field of Scientific and Technical Research (COST).

"We found that natural products provide invaluable leads for drug discovery and opportunities to explore chemical and biological pathways, both of which are essential to advancing the life sciences," said the conference chair K.C. Nicolaou from the Scripps Research Institute in the US. Some of the products discussed at the conference were ready for preclinical development, having shown great potential for treating a range of infectious and metabolic diseases as well as cancers.

Such products are creating excitement because they promise to combine more effective treatment with reduced side effects, as well exploiting clean non-toxic synthetic techniques. For example Maurizio Botta from the University of Sienna in Italy discussed the design, synthesis and biological evaluation of new compounds for tackling AIDS and HIV by inhibiting reverse transcriptase, the process by which this type of retrovirus virus hijacks the host cell's genetic machinery to replicate itself. Some of these compounds have already exhibited strong activity against the AIDS virus in the laboratory.

There were also a number of promising anti-bacterial agents presented at the conference, which is an important development given the growing resistance of some bacterial species to existing antibiotics and the growing problem posed by MRSA, the "super bug" that plagues many hospitals and nursing homes. Dionisios Vourloumis, research director at the state run Greek research centre NCSR Demokritos, explained how bacteria could be disabled by targeting the RNA binding molecules needed for their genes to be expressed.

It is important to distinguish between the highly specific compounds being developed by researchers in natural products, and existing herbal remedies that often have dubious therapeutic value. "The difference from herbal medicine is that chemists are talking about pure active ingredients, precisely defined at the molecular level, as opposed to crude, multi-component mixtures of compounds contained in herbal medicines," said Nicolaou.

Although, as Nicolaou emphasised, the main focus of the natural products field is on drug discovery and exploitation of biological pathways to treat disease, the synthetic processes involved also have great potential for developing novel products for a variety of industrial applications, particularly in the chemical industry. One active area of research lies in harnessing the reaction centres of photosynthesis to produce clean sustainable energy converted from the sun without using fossil fuels, just as plants do. This could either be done by engineering new types of plant or photosynthesising cyanobacteria, or mimicking these processes to synthesise artificial systems that perhaps are more convenient to deploy.

The synthetic strategies developed to synthesize natural products also have great potential for green chemistry, involving manufacture of compounds for different applications using sustainable techniques that reduce or eliminate toxic by-products, for example in the paper manufacturing industry. The overall focus was in harnessing the tools of chemistry to develop new techniques for synthesising organic compounds for a variety of purposes, with improved efficiency and sustainability.

The ESF-COST conference on Natural Products Chemistry, Biology and Medicine was held near Naples in Italy in May 2008.

For further information, please visit:
http://www.esf.org/activities/esf-conferences/partnerships/
esf-cost-high-level-research-conferences.html

Most Popular Now

FDA grants Breakthrough Therapy Designation to Pfi…

Pfizer Inc. (NYSE:PFE) today announced that its investigational Group B Streptococcus (GBS) vaccine candidate, GBS6 or PF-06760805, received Breakthrough Therapy Designat...

Novartis invests in early technical development ca…

Novartis today announced it is investing in next-generation biotherapeutics with the creation of a fully integrated, dedicated USD 300m scientific environment that will b...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a 30-µg booster dose of their Omicron BA.4/BA.5 bivalent-adapted COVID-19 vaccine (COMIRNATY® Original/Om...

Malaria booster vaccine shows durable high efficac…

Researchers from the University of Oxford and their partners have today reported new findings from their Phase 2b trial following the administration of a booster dose of ...

Strict COVID lockdowns in France improved cardiova…

A new paper in European Heart Journal - Digital Health, published by Oxford University Press, indicates that social-distancing measures like total lockdown have a measura...

U.S. clinical trial evaluating antiviral for monke…

A Phase 3 clinical trial evaluating the antiviral tecovirimat, also known as TPOXX, is now enrolling adults and children with monkeypox infection in the United States. St...

Stem cell-gene therapy shows promise in ALS safety…

Cedars-Sinai investigators have developed an investigational therapy using support cells and a protective protein that can be delivered past the blood-brain barrier. This...

Drug turns cancer gene into "eat me" fla…

Tumor cells are notoriously good at evading the human immune system; they put up physical walls, wear disguises and handcuff the immune system with molecular tricks. Now...

Mucosal antibodies in the airways protect against …

High levels of mucosal antibodies in the airways reduce the risk of being infected by omicron, but many do not receive detectable antibodies in the airways despite three ...

WHO grants prequalification to GSK's Mosquirix - t…

GSK plc (LSE/NYSE: GSK) announced that the World Health Organization (WHO) has awarded prequalification to Mosquirix (also known as RTS,S/AS01), GSK's groundbreaking mala...

Bird's enzyme points toward novel therapies

Thank the rare crested ibis for a clue that could someday help our bodies make better drugs. The species of bird is the only one known to naturally produce an enzyme ...

WHO strongly advises against antibody treatments f…

The antibody drugs sotrovimab and casirivimab-imdevimab are not recommended for patients with COVID-19, says a WHO Guideline Development Group of international experts in...